Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME Day

Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry representatives urge policy reforms, including energy access and expanded PLI schemes, to bolster competitiveness. Delayed GST refunds and liquidity issues further challenge smaller drug manufacturers, impacting their ability to compete globally and respond to disruptions.